{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:24:47Z","timestamp":1740108287277,"version":"3.37.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Geran Galakan Penyelidik Muda","award":["GGPM-2019-054"],"award-info":[{"award-number":["GGPM-2019-054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00198-022-06444-5","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T20:02:50Z","timestamp":1654027370000},"page":"1909-1923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-0617","authenticated-orcid":false,"given":"Y. W.","family":"Choo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-4799","authenticated-orcid":false,"given":"N. A.","family":"Mohd Tahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-1844","authenticated-orcid":false,"given":"M. S.","family":"Mohamed Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-3095","authenticated-orcid":false,"given":"S. C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0592-0645","authenticated-orcid":false,"given":"M.","family":"Makmor Bakry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"6444_CR1","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00198-015-3154-6","volume":"26","author":"A Od\u00e9n","year":"2015","unstructured":"Od\u00e9n A, McCloskey EV, Kanis JA et al (2015) Burden of high fracture probability worldwide: secular increases 2010\u20132040. Osteoporos Int 26:2243\u20132248. https:\/\/doi.org\/10.1007\/s00198-015-3154-6","journal-title":"Osteoporos Int"},{"key":"6444_CR2","unstructured":"Department of Statistics Malaysia (2016) Population Projection (Revised), Malaysia, 2010\u20132040. Malaysia"},{"key":"6444_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.afos.2018.03.003","volume":"4","author":"C-L Cheung","year":"2018","unstructured":"Cheung C-L, Bin AS, Chadha M et al (2018) An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. Osteoporos Sarcopenia 4:16\u201321. https:\/\/doi.org\/10.1016\/j.afos.2018.03.003","journal-title":"Osteoporos Sarcopenia"},{"key":"6444_CR4","unstructured":"Pharmaceutical Services Programme (2021) Official Portal of Pharmaceutical Services Programme, Ministry of Health Malaysia. https:\/\/www.pharmacy.gov.my\/v2\/en. Accessed 21 Apr 2021"},{"key":"6444_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:e027049. https:\/\/doi.org\/10.1136\/bmjopen-2018-027049","journal-title":"BMJ Open"},{"key":"6444_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00198-019-05154-9","volume":"31","author":"D Cornelissen","year":"2020","unstructured":"Cornelissen D, Boonen A, Bours S et al (2020) Understanding patients\u2019 preferences for osteoporosis treatment: the impact of patients\u2019 characteristics on subgroups and latent classes. Osteoporos Int 31:85\u201396. https:\/\/doi.org\/10.1007\/s00198-019-05154-9","journal-title":"Osteoporos Int"},{"key":"6444_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jot.2019.08.004","volume":"22","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Huang Z, Wang Y et al (2020) The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: a review. J Orthop Transl 22:7\u201313. https:\/\/doi.org\/10.1016\/j.jot.2019.08.004","journal-title":"J Orthop Transl"},{"key":"6444_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3111\/13696998.2012.737393","volume":"15","author":"D Chau","year":"2012","unstructured":"Chau D, Becker DL, Coombes ME et al (2012) Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ 15:3\u201314. https:\/\/doi.org\/10.3111\/13696998.2012.737393","journal-title":"J Med Econ"},{"key":"6444_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CEOR.S78349","volume":"7","author":"J Darb\u00e0","year":"2015","unstructured":"Darb\u00e0 J, Kaskens L, Vilela FS, Lothgren M (2015) Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Clin Outcomes Res 7:105\u2013117. https:\/\/doi.org\/10.2147\/CEOR.S78349","journal-title":"Clin Outcomes Res"},{"key":"6444_CR10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","volume":"29","author":"M Hiligsmann","year":"2011","unstructured":"Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29:895\u2013911. https:\/\/doi.org\/10.2165\/11539980-000000000-00000","journal-title":"Pharmacoeconomics"},{"key":"6444_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B J\u00f6nsson","year":"2011","unstructured":"J\u00f6nsson B, Str\u00f6m O, Eisman JA et al (2011) Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967\u2013982. https:\/\/doi.org\/10.1007\/s00198-010-1424-x","journal-title":"Osteoporos Int"},{"key":"6444_CR12","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00198-017-3940-4","volume":"28","author":"T Mori","year":"2017","unstructured":"Mori T, Crandall CJ, Ganz DA (2017) Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan. Osteoporos Int 28:1733\u20131744. https:\/\/doi.org\/10.1007\/s00198-017-3940-4","journal-title":"Osteoporos Int"},{"key":"6444_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse M, Yurgin N et al (2013) Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy 11:485\u2013497. https:\/\/doi.org\/10.1007\/s40258-013-0047-8","journal-title":"Appl Health Econ Health Policy"},{"key":"6444_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11657-018-0509-6","volume":"13","author":"T Yoshizawa","year":"2018","unstructured":"Yoshizawa T, Nishino T, Okubo I, Yamazaki M (2018) Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate. Arch Osteoporos 13:94. https:\/\/doi.org\/10.1007\/s11657-018-0509-6","journal-title":"Arch Osteoporos"},{"key":"6444_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12962-016-0060-5","volume":"14","author":"J Karnon","year":"2016","unstructured":"Karnon J, Shafie AS, Orji N, Usman SK (2016) What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost Eff Resour Alloc 14:11. https:\/\/doi.org\/10.1186\/s12962-016-0060-5","journal-title":"Cost Eff Resour Alloc"},{"key":"6444_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1080\/13696998.2020.1730381","volume":"23","author":"C Pongchaiyakul","year":"2020","unstructured":"Pongchaiyakul C, Nanagara R, Songpatanasilp T, Unnanuntana A (2020) Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand. J Med Econ 23:776\u2013785. https:\/\/doi.org\/10.1080\/13696998.2020.1730381","journal-title":"J Med Econ"},{"key":"6444_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00198-006-0257-0","volume":"18","author":"N Zethraeus","year":"2007","unstructured":"Zethraeus N, Borgstr\u00f6m F, Str\u00f6m O et al (2007) Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int 18:9\u201323. https:\/\/doi.org\/10.1007\/s00198-006-0257-0","journal-title":"Osteoporos Int"},{"key":"6444_CR18","unstructured":"Ministry of Health Malaysia (2015) Clinical Guidance on Management of Osteoporosis, Second edi. Ministry of Health Malaysia, Malaysia"},{"key":"6444_CR19","unstructured":"Ministry of Health Malaysia (2019) Pharmacoeconomic Guidelines for Malaysia, Second edi. Ministry of Health Malaysia, Malaysia"},{"key":"6444_CR20","unstructured":"World Health Organization, Baltussen, Rob M. P. M, Adam, Taghreed, Tan-Torres Edejer, Tessa, Hutubessy, Raymond CW et al (\u200e2003)\u200e Making choices in health: WHO guide to cost-effectiveness analysis \/ edited by T. Tan-Torres Edejer ... [\u200eet al]\u200e. Geneva: World Health Organization"},{"key":"6444_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY, Tosteson ANA et al (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and. Osteoporos Int 30:45\u201357. https:\/\/doi.org\/10.1007\/s00198-018-4744-x","journal-title":"Osteoporos Int"},{"key":"6444_CR22","doi-asserted-by":"publisher","unstructured":"Husereau D, Drummond M, Augustovski F et al (2022) Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics 2022https:\/\/doi.org\/10.1007\/s40273-021-01112-8","DOI":"10.1007\/s40273-021-01112-8"},{"key":"6444_CR23","unstructured":"Medical Development Division (2021) Malaysian DRG Executive Information System. In: Minist. Heal. Malaysia. http:\/\/casemix-eis.moh.gov.my\/. Accessed 1 Feb 2021"},{"key":"6444_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721\u2013739. https:\/\/doi.org\/10.1359\/jbmr.2000.15.4.721","journal-title":"J Bone Miner Res"},{"key":"6444_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","volume":"25","author":"RL Fleurence","year":"2007","unstructured":"Fleurence RL, Hollenbeak CS (2007) Rates and probabilities in economic modelling: Transformation, translation and appropriate application. Pharmacoeconomics 25:3\u20136. https:\/\/doi.org\/10.2165\/00019053-200725010-00002","journal-title":"Pharmacoeconomics"},{"key":"6444_CR26","unstructured":"Department of Statistics Malaysia (2020) Vital Statistics, Malaysia, 2020. Malaysia"},{"key":"6444_CR27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00198-015-3238-3","volume":"27","author":"CY Chang","year":"2016","unstructured":"Chang CY, Tang CH, Chen KC et al (2016) The mortality and direct medical costs of osteoporotic fractures among postmenopausal women in Taiwan. Osteoporos Int 27:665\u2013676. https:\/\/doi.org\/10.1007\/s00198-015-3238-3","journal-title":"Osteoporos Int"},{"key":"6444_CR28","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00198-016-3576-9","volume":"27","author":"YC Ha","year":"2016","unstructured":"Ha YC, Kim TY, Lee A et al (2016) Current trends and future projections of hip fracture in South Korea using nationwide claims data. Osteoporos Int 27:2603\u20132609. https:\/\/doi.org\/10.1007\/s00198-016-3576-9","journal-title":"Osteoporos Int"},{"key":"6444_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3346\/jkms.2016.31.4.630","volume":"31","author":"GD Kwon","year":"2016","unstructured":"Kwon GD, Jang S, Lee A et al (2016) Incidence and mortality after distal radius fractures in adults aged 50 years and older in Korea. J Korean Med Sci 31:630\u2013634. https:\/\/doi.org\/10.3346\/jkms.2016.31.4.630","journal-title":"J Korean Med Sci"},{"key":"6444_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3346\/jkms.2016.31.5.801","volume":"31","author":"TY Kim","year":"2016","unstructured":"Kim TY, Jang S, Park CM et al (2016) Trends of incidence, mortality, and future projection of spinal fractures in Korea using nationwide claims data. J Korean Med Sci 31:801\u2013805. https:\/\/doi.org\/10.3346\/jkms.2016.31.5.801","journal-title":"J Korean Med Sci"},{"key":"6444_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11657-016-0289-9","volume":"11","author":"S Li","year":"2016","unstructured":"Li S, Sun T, Liu Z (2016) Excess mortality of 1 year in elderly hip fracture patients compared with the general population in Beijing, China. Arch Osteoporos 11:35. https:\/\/doi.org\/10.1007\/s11657-016-0289-9","journal-title":"Arch Osteoporos"},{"key":"6444_CR32","doi-asserted-by":"publisher","unstructured":"Man LP, Angela Ho AWH, Wong SH (2016) Excess mortality for operated geriatric hip fracture in Hong Kong. Hong Kong Med J 22:6\u201310. https:\/\/doi.org\/10.12809\/hkmj154568","DOI":"10.12809\/hkmj154568"},{"key":"6444_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O et al (2003) The components of excess mortality after hip fracture. Bone 32:468\u2013473. https:\/\/doi.org\/10.1016\/S8756-3282(03)00061-9","journal-title":"Bone"},{"key":"6444_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O et al (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108\u2013112. https:\/\/doi.org\/10.1007\/s00198-003-1516-y","journal-title":"Osteoporos Int"},{"key":"6444_CR35","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2019-00192","journal-title":"J Clin Endocrinol Metab"},{"key":"6444_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-008-0644-9","volume":"20","author":"O Str\u00f6m","year":"2009","unstructured":"Str\u00f6m O, Borgstr\u00f6m F, Kanis JA, J\u00f6nsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23\u201334. https:\/\/doi.org\/10.1007\/s00198-008-0644-9","journal-title":"Osteoporos Int"},{"key":"6444_CR37","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00198-017-4144-7","volume":"28","author":"C Reyes","year":"2017","unstructured":"Reyes C, Tebe C, Martinez-Laguna D et al (2017) One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int 28:2997\u20133004. https:\/\/doi.org\/10.1007\/s00198-017-4144-7","journal-title":"Osteoporos Int"},{"key":"6444_CR38","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00198-016-3623-6","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Kyvernitakis I, Kann PH et al (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27:2967\u20132978. https:\/\/doi.org\/10.1007\/s00198-016-3623-6","journal-title":"Osteoporos Int"},{"key":"6444_CR39","doi-asserted-by":"publisher","unstructured":"Cheng LI, Durden E, Limone B et al (2015) Persistence and compliance with osteoporosis therapies among women in a commercially insured population in the United States. J Manag Care Pharm 21:824\u2013833. https:\/\/doi.org\/10.18553\/jmcp.2015.21.9.824","DOI":"10.18553\/jmcp.2015.21.9.824"},{"key":"6444_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11657-017-0316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L et al (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12:22. https:\/\/doi.org\/10.1007\/s11657-017-0316-5","journal-title":"Arch Osteoporos"},{"key":"6444_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00223-015-0082-6","volume":"98","author":"P Lakatos","year":"2016","unstructured":"Lakatos P, Tak\u00e1cs I, Marton I et al (2016) A retrospective longitudinal database study of persistence and compliance with treatment of osteoporosis in Hungary. Calcif Tissue Int 98:215\u2013225. https:\/\/doi.org\/10.1007\/s00223-015-0082-6","journal-title":"Calcif Tissue Int"},{"key":"6444_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00198-019-05228-8","volume":"31","author":"J Morley","year":"2020","unstructured":"Morley J, Moayyeri A, Ali L et al (2020) Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int 31:533\u2013545. https:\/\/doi.org\/10.1007\/s00198-019-05228-8","journal-title":"Osteoporos Int"},{"key":"6444_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/PPA.S46192","volume":"8","author":"T Miyazaki","year":"2014","unstructured":"Miyazaki T, Tokimura F, Tanaka S (2014) A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence 8:463\u2013471. https:\/\/doi.org\/10.2147\/PPA.S46192","journal-title":"Patient Prefer Adherence"},{"key":"6444_CR44","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/nejmoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer J-P et al (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199. https:\/\/doi.org\/10.1056\/nejmoa030897","journal-title":"N Engl J Med"},{"key":"6444_CR45","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial long-term extension (FLEX): a randomized trial. J Am Med Assoc 296:2927\u20132938. https:\/\/doi.org\/10.1001\/jama.296.24.2927","journal-title":"J Am Med Assoc"},{"key":"6444_CR46","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD et al (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732. https:\/\/doi.org\/10.1007\/s00198-017-3919-1","journal-title":"Osteoporos Int"},{"key":"6444_CR47","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","volume":"22","author":"DL Kendler","year":"2011","unstructured":"Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725\u20131735. https:\/\/doi.org\/10.1007\/s00198-010-1378-z","journal-title":"Osteoporos Int"},{"key":"6444_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161. https:\/\/doi.org\/10.1359\/jbmr.0809010","journal-title":"J Bone Miner Res"},{"key":"6444_CR49","unstructured":"World Bank Group (2021) GDP deflator (base year varies by country) - Malaysia. https:\/\/data.worldbank.org\/indicator\/NY.GDP.DEFL.ZS?end=2019&locations=MY&start=2010. Accessed 15 Feb 2021"},{"key":"6444_CR50","unstructured":"Central Bank of Malaysia (2021) Exchange Rates 2019. https:\/\/www.bnm.gov.my\/exchange-rates. Accessed 1 Mar 2021"},{"key":"6444_CR51","volume-title":"Fees (Medical) (Cost of Services) Order 2014","author":"Federal Government Gazette","year":"2014","unstructured":"Federal Government Gazette (2014) Fees (Medical) (Cost of Services) Order 2014. Attorney General\u2019s Chambers, Malaysia"},{"key":"6444_CR52","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","volume":"14","author":"R Ara","year":"2011","unstructured":"Ara R, Brazier JE (2011) Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Heal 14:539\u2013545. https:\/\/doi.org\/10.1016\/j.jval.2010.10.029","journal-title":"Value Heal"},{"key":"6444_CR53","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00198-014-2636-2","volume":"25","author":"L Si","year":"2014","unstructured":"Si L, Winzenberg TM, De Graaff B, Palmer AJ (2014) A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporos Int 25:1987\u20131997. https:\/\/doi.org\/10.1007\/s00198-014-2636-2","journal-title":"Osteoporos Int"},{"key":"6444_CR54","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jval.2017.04.002","volume":"20","author":"YW Lim","year":"2017","unstructured":"Lim YW, Shafie AA, Chua GN, Ahmad Hassali MA (2017) Determination of cost-effectiveness threshold for health care interventions in Malaysia. Value Heal 20:1131\u20131138. https:\/\/doi.org\/10.1016\/j.jval.2017.04.002","journal-title":"Value Heal"},{"key":"6444_CR55","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K (2006) Decision modelling for health economic evaluation. Oxford University Press"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06444-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06444-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06444-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T13:21:26Z","timestamp":1700659286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06444-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6444"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06444-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"11 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YWC, MSMS, MMB, SCL, and NAMT declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}